Development and characterization of a tamoxifen-resistant breast carcinoma xenograft

British Journal of Cancer

Volumn 82, Issue 11, 2000, Pages 1844-1850

  Naundorf, H ^a   Becker, M ^a   Lykkesfeldt, A E ^b   Elbe, B ^a   Neumann, C ^a   Buttner B ^a   Fichtner, I ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Breast cancer; Cathepsin D gene; Oestrogen receptor; pS2 gene; Tamoxifen resistance; Xenograft

Indexed keywords

CATHEPSIN D; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; PROTEIN PS2; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; CROSS RESISTANCE; FEMALE; GENE MUTATION; HISTOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR GENE; XENOGRAFT;

EID: 0034030320     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1156     Document Type: Article

References (46)

1. Augereau P, Garcia M, Mattei MG, Cavailles V, Depadova F, Deroeq D, Capony F, Ferrara P and Rochefort H (1988) Cloning and sequencing of the 52K cathepsin D complementary deoxyribonucleic acid of MCF-7 breast cancer cells and mapping on chromosome II. Mol Endocrinol 2: 186-192
2. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JA and Nilsson S (1998) Differential response of oestrogen receptor α and oestrogen receptor β to partial oestrogen agonists/antagonists. Mol Pharmacol 54: 105-112
3. Brzozowski AM, Pike ACW, Dauter Z, Hubbart RE, Bonn T, Engström O, Öhman L, Green GL, Gustafsson JA and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758
4. Clarke R (1996) Human breast cancer cell line xenografts as models of breast cancer - The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 39: 69-86
5. Denton RR, Koszewski NJ and Notides AC (1992) Oestrogen receptor phosphorylation. Hormonal dependence and consequence on specific DNA binding. J Biol Chem 267: 7263-7268
6. Early Breast Cancer Trial Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339: 1-15, 71-85
7. Foekens JA, Portengen H, Look MP, van Putten WLJ, Thirion B, Bontenbal M and Klijn JGM (1994) Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 70: 1217-1223
8. Gottardis MM and Jordan VC (1988) Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term anti-oestrogen administration. Cancer Res 48: 5183-5187
9. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P and Chambon P (1986) Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320: 134-139
10. Jensen BL, Skouv J, Lundholt BK and Lykkesfeldt AE (1999) Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6. Br J Cancer 79: 386-392
11. Johnston SRD, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR and Dowsett M (1995) Changes in oestrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55: 3331-3338
12. Karnik PS, Julkarni S, Liu XP, Budd T and Bukowski RM (1994) Oestrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54: 349-353
13. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME and McInerney EM (1997) Anti-oestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 44: 23-38
14. Landel CC, Kushner PJ and Greene GL (1994) The interaction of human oestrogen receptor with DNA is modulated by receptor-associated proteins. Mol Endocrinol 8: 1407-1419
15. Laborda J (1991) 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 19: 3998
16. Larsen SS, Madsen MW, Jensen BL and Lykkesfeldt AE (1997) Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int J Cancer 72: 1129-1136
17. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG and Rose DW (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920-2925
18. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275
19. R-1. Cancer Res 54: 1587-1595
20. Lykkesfeldt AE (1996) Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol 5(Suppl): 9-14
21. Lykkesfeldt AE (1997) Growth regulation of human breast cancer cells by oestrogens and anti-oestrogens ISBN-no: 87-90212-14-2
22. Maalouf GJ, Xu W, Smith TF and Mohr SC (1998) Homology model for the ligand-binding domain of the human estrogen receptor. J Biomol Struct Dvn 15: 841-851
23. Madsen MW, Lykkesfeldt AE, Laursen I, Nielsen KV and Briand P (1992) Altered gene expression of c-myc, epidermal growth factor receptor, transforming growth factor-alpha, and c-erb-B2 in an immortalized human breast epithelial cell line, HMT-3522, is associated with decreased growth factor requirements. Cancer Res 52: 1210-1217
24. Madsen MW, Reiter BE, Larson SS, Briand P and Lykkesfeldt, AE (1997) Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57: 585-589
25. Mahfoudi A, Roulet E, Dauvois S, Parker MG and Wahli W (1995) Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92: 4206-4210
26. Martin MB, Saceda M. Garcia-Morales P and Gottardis MM (1994) Regulation of estrogen receptor expression. Breast Cancer Res Treat 31: 183-189
27. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A and Chambon P (1982) Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895-7903
28. Montano MM, Muller V, Trobaugh A and Katzenellenbogen BS (1995) The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9: 814-825
29. Montella M, Biondi E, deMarco M, Cerra M, Cecco L, Botti G, Bonelli P and Tuccillo F (1996) Breast cancer estrogen and progesterone receptors: a multivariate analysis of associations with clinical and histologic characteristics in a series of 2933 consecutive cases. International Journal of Oncology 9: 977-982
30. Murphy CS, Langan-Fahey SM, McCague R and Jordan VC (1990) Structure-function relationship of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vivo. Mol Pharmacol 38: 737-743
31. Murphy LC, Wang M, Coutt A and Dotzlaw H (1996) Novel mutations in the estrogen receptor messenger RNA in human breast cancers. J Clin Endocrinol Metab 81: 1420-1427
32. Naundorf H and Arnold W (1981) Breeding of nude mice under improved conditions. Zeitschrift fur Versuchstierkunde 23: 77-79
33. Naundorf H, Fichtner I, Büttner B and Frege J (1992) Establishment and characterization of a new human oestradiol - and progesterone-receptor-positive mammary carcinoma serially transplantable in nude mice. J Cancer Res Clin Oncol 119: 35-40
34. Noguchi S, Motomura K, Inaji H, Imaoka S and Koyama H (1993) Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 71: 1266-1272
35. Osborne CK, Coronado EB and Robinson JP (1987) Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. European Journal of Cancer and Clinical Oncology 23: 1189-1196
36. Osborne CK and Fuqua SAW (1994) Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 32: 49-55
37. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JA, Kushner PJ and Scanlan TS (1997) Differential ligand activation of oestrogen receptors ERα and ERβ at AP1 sites. Science 277: 1508-1510
38. Pink JJ and Jordan VC (1996) Models of estrogen receptor regulation by oestrogens and antiestrogens in breast cancer cell lines. Cancer Res 56: 2321-2330
39. Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R and Chambon P (1987) Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 84: 9243-9247
40. Thompson EW, Brünner N, Torri J, Johnson MD, Boulay V, Wright A, Lippman ME, Steeg PS and Clarke R (1993) The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis 11: 15-26
41. Tonetti DA and Jordan VC (1995) Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs 6: 498-507
42. Tonetti DA and Jordan VC (1997) The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J Steroid Biochem Mol Biol 62: 119-128
43. van Agthoven T, van Agthoven TLA, Dekker A, van der Spek PJ, Vreede L and Dorssers LCJ (1998) Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17: 2799-2808
44. Westley B and Rochefort H (1980) A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20: 353-362
45. Westley B, May FEB, Brown AMC, Krust A, Chambon P, Lippman ME and Rochefort H (1984) Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52-and 160-kilodalton proteins in MCF-7 cells and two tamoxifen resistant sublines. J Biol Chem 259: 10030-10035
46. Wolf DM and Jordan VC (1994) Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat 31: 117-127